Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.64 |
| ▸ | BRD4 | O60885 | 3/20 | 0.61 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.60 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.60 |
| ▸ | TNF | P01375 | 1/20 | 0.60 |
| ▸ | IL1B | P01584 | 1/20 | 0.60 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.60 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.56 |
| ▸ | MAP1LC3B | Q9GZQ8 | 3/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29679352 | 1.00 | CRBN (0.64) | CRBNBRD4IKZF1IKZF3TNF | |
| SCHEMBL13641027 | 0.92 | CRBN (0.62) | CRBNBRD4IKZF1IKZF3TNF | |
| SCHEMBL30249970 | 0.91 | CRBN (0.65) | CRBNBRD4IKZF1IKZF3TNF | |
| SCHEMBL805995 | 0.90 | CRBN (0.60) | CRBNBRD4IKZF1IKZF3TNF | |
| SCHEMBL25263045 | 0.90 | CRBN (0.64) | CRBNBRD4IKZF1IKZF3TNF | |
| SCHEMBL22464605 | 0.90 | CRBN (0.64) | CRBNBRD4IKZF1IKZF3TNF | |
| SCHEMBL29453444 | 0.90 | CRBN (0.64) | CRBNBRD4IKZF1IKZF3TNF | |
| SCHEMBL2383001 | 0.90 | CRBN (0.64) | CRBNBRD4IKZF1IKZF3TNF | |
| SCHEMBL2384439 | 0.90 | CRBN (0.64) | CRBNBRD4IKZF1IKZF3TNF | |
| SCHEMBL26321021 | 0.90 | CRBN (0.64) | CRBNBRD4IKZF1IKZF3TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168958-A1 | Isoindole-Imide Compounds, Compositions And Uses Thereof | CELGENE CORPORATION (US) | 2010-03-31 | — | — | EP | claimed |
| EP-1363900-A1 | ISOINDOLE-IMIDE COMPOUNDS AS TNF-INHIBITORS | CELGENE CORPORATION (US) | 2003-11-26 | — | — | EP | claimed |
| US-20030096841-A1 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION | 2003-05-22 | — | — | US | claimed |
| US-20030045552-A1 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION | 2003-03-06 | — | — | US | claimed |
| WO-2002059106-A1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CELGENE CORPORATION (US) | 2002-08-01 | — | — | WO | claimed |
| US-20230312575-A1 | LIGANDS TO CEREBLON (CRBN) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-05 | — | — | US | disclosed |
| WO-2023115150-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023097251-A1 | OLIGONUCLEOTIDE-CONTAINING TRANSCRIPTION FACTOR TARGETING CHIMERAS | YALE UNIVERSITY (US) | 2023-06-01 | — | — | WO | disclosed |
| US-20210369853-A1 | TARGETED PROTEASE DEGRADATION PLATFORM | EUBULUS BIOTHERAPEUTICS INC. (CN) | 2021-12-02 | — | — | US | disclosed |
| EP-3865152-A1 | TARGETED PROTEASE DEGRADATION PLATFORM | Eubulus Biotherapeutics Inc. (CN) | 2021-08-18 | — | — | EP | disclosed |
| US-20200331889-A1 | COMPOUNDS FOR THE DEGRADATION OF STK4 AND TREATMENT OF HEMATOLOGIC MALIGNANCIES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-22 | — | — | US | disclosed |
| EP-2582836-B1 | PRPK-TPRKB MODULATORS AND USES THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2018-03-07 | — | — | EP | disclosed |
| US-20090286986-A1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CELGENE CORPORATION | 2009-11-19 | — | — | US | disclosed |
| US-20090286986-A1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CELGENE CORPORATION | 2009-11-19 | — | — | US | disclosed |
| US-7576104-B2 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576104-B2 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576104-B2 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1767533-A1 | N-{(2-(2,6-dioxo(3-piperidyl)-1,3-dioxo-2,3-dihydro-1H-isoindolin-4-yl)methyl}cyclopropylcarboxamide as TNF inhibitor | CELGENE CORPORATION (US) | 2007-03-28 | — | — | EP | disclosed |
| US-7091353-B2 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060025597-A1 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045552-A1 | Isoindole-imide compounds, compositions, and uses thereof | TNF, IKZF3, IKZF1 | CRBN 1511/4885BRD4 1719/4885IKZF1 3/4885 |
| US-20090286986-A1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS, AND USES THEREOF | TNF, IKZF3, TNFRSF1A | CRBN 1695/4885BRD4 2140/4885IKZF1 4/4885 |
| US-20060025597-A1 | Isoindole-imide compounds, compositions, and uses thereof | TNF, IKZF3, TNFRSF1A | CRBN 1695/4885BRD4 2140/4885IKZF1 4/4885 |
| US-20030096841-A1 | Isoindole-imide compounds, compositions, and uses thereof | TNF, IKZF3, IKZF1 | CRBN 1511/4885BRD4 1719/4885IKZF1 3/4885 |
| US-20230312575-A1 | LIGANDS TO CEREBLON (CRBN) | CRBN, CRKL, CDR2 | CRBN 1/4885BRD4 902/4885IKZF1 443/4885 |
| US-20210369853-A1 | TARGETED PROTEASE DEGRADATION PLATFORM | PSMB1, MDM2, XIAP | CRBN 284/4885BRD4 1676/4885IKZF1 1743/4885 |
| US-20200331889-A1 | COMPOUNDS FOR THE DEGRADATION OF STK4 AND TREATMENT OF HEMATOLOGIC MALIGNANCIES | STK4, STK11, STK16 | CRBN 401/4885BRD4 673/4885IKZF1 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.